We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01547910
First Posted: March 8, 2012
Last Update Posted: August 21, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Medical University of Bialystok
Medical University of Silesia
Pediatric Municipal Hospital of Rzeszow, Poland
Information provided by (Responsible Party):
Piotr Socha, Children's Memorial Health Institute, Poland
  Purpose
The aim of this study is to evaluate efficacy of fish oil (EPA/DHA) in children with non-alcoholic fatty liver disease.

Condition Intervention Phase
Non-alcoholic Fatty Liver Disease Dietary Supplement: Fish Oil Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children - a Randomized, Double Blind, Placebo Controlled, Multicenter Study

Resource links provided by NLM:


Further study details as provided by Piotr Socha, Children's Memorial Health Institute, Poland:

Primary Outcome Measures:
  • Serum alanine transaminase level decrease min. 0.3 upper limit of normal [ Time Frame: 6 months ]
    Number of patients in whom ALT decreased min. 0.,3 ULN in 'fish oil' group compared to 'placebo' group


Secondary Outcome Measures:
  • normalization of liver imaging on ultrasound [ Time Frame: after 6 months of therapy ]
    'Fish oil' group will be compared to 'placebo' group

  • ALT and AST activity [ Time Frame: 6 months ]
    'Fish oil' group will be compared to 'placebo' group

  • Insulin resistance markers as Homa-IR [ Time Frame: 6 months ]
    'Fish oil' group will be compared to 'placebo' group

  • Fat and lean body mass measurements [ Time Frame: 6 months ]
    'Fish oil' group will be compared to 'placebo' group

  • Caloric intake including fat intake and sucrose intake [ Time Frame: 6 months ]
    'Fish oil' group will be compared to 'placebo' group


Enrollment: 76
Study Start Date: August 2007
Study Completion Date: April 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fish oil
Children will receive fish oil capsules according to age as described in the protocol
Dietary Supplement: Fish Oil
Fish oil given in supplementary dose
Placebo Comparator: Placebo
Sunflower oil in the same capsules (the same shape and colour) given in the same regime as 'fish oil' capsules
Dietary Supplement: Fish Oil
Fish oil given in supplementary dose

Detailed Description:
76 children or adolescents aged 6-19 with NAFLD will be included in the study. Diagnosis of NAFLD is set by increased alanine transaminase and features of liver steatosis on ultrasound. Patients will be randomized to receive either fish oil (EPA/DHA, 400-1200mg) or placebo (sunflower oil) for 6 months. All children will be advised to reduce weight (dietetic intervention + increased physical activity). Laboratory tests, liver ultrasound, anthropometric analysis will be performed at the start, after 3 months and 6 months.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Years to 19 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • age 6-19
  • overweight or obesity
  • ALT activity over 130% of upper limit norm
  • hyperechogenicity of the liver on ultrasound

Exclusion Criteria:

  • HCV, HBV infection
  • cholestasis
  • chronic/acute liver failure
  • alpha-1-antitrypsin deficiency
  • Wilson disease
  • type 2 diabetes mellitus
  • beta-oxidation defects
  • alcohol consumption
  • history of parenteral nutrition
  • use of drugs
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01547910


Sponsors and Collaborators
Piotr Socha
Medical University of Bialystok
Medical University of Silesia
Pediatric Municipal Hospital of Rzeszow, Poland
Investigators
Principal Investigator: Piotr Socha Children's Memorial Health Institute, Warsaw, Poland
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Piotr Socha, Professor PhD MD, Principal Investigator, Children's Memorial Health Institute, Poland
ClinicalTrials.gov Identifier: NCT01547910     History of Changes
Other Study ID Numbers: ChildrensMHIPoland
First Submitted: February 29, 2012
First Posted: March 8, 2012
Last Update Posted: August 21, 2014
Last Verified: August 2014

Keywords provided by Piotr Socha, Children's Memorial Health Institute, Poland:
fatty liver
hepatitis
insulin resistance
unsaturated fatty acids
NAFLD, children

Additional relevant MeSH terms:
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases